Health
New Covid-19 vaccine demonstrates ’89 efficacy’ with UK having 60m orders – Bridport and Lyme Regis News
A trial was carried out in conjunction with the UK Government’s Vaccine Taskforce.
An experimental Covid-19 vaccine appears to offer strong protection in late-stage UK and South Africa studies, said manufacturer Novavax.The UK has secured access to 60 million doses of the vaccine, called NVX-CoV2373.The protein-based vaccine candidate was shown to be 89.3% effective at preventing coronavirus in participants in its Phase 3 clinical trial in the UK, which enrolled more than 15,000 people between 18-84, of which 27% were older than 65, Novavax said.
“NVX-CoV2373 is the first vaccine…
-
Noosa News17 hours agoHow Lily Steele-Park took her rapist to court and won
-
Business22 hours agoFord CEO makes stunning prediction about artificial intelligence
-
General23 hours agoRush to buy homes before rate cuts send prices soaring
-
Business20 hours ago5 things to watch on the ASX 200 on Tuesday 8 July 2025